Registry for Estimation of Warfarin and Rivaroxaban in Atrial Fibrillation Patients With Coronary Stent Implantation
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Antiplatelet therapy is indispensable for the prevention of stent thrombosis in patients who
underwent coronary artery stenting. Similarly, anticoagulant therapy is essential for the
prevention of cardiogenic embolism including cerebral infarction in AF patients. However, the
combined antithrombotic therapy has been reported to increase the risk of major bleeding for
AF patients after coronary stenting, New anticoagulant drugs that hardly interact with other
drugs and do not need frequent blood tests have become commonly used. The purpose of this
study is to assess the hypothesis that Rivaroxaban is non-inferior to Warfarin in the
efficacy and safety for AF patients after coronary stenting.